PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Rudbeckia hirta, commonly known as Black-eyed Susan, is a flowering plant with traditional uses in managing inflammatory conditions and digestive ailments [PMID:37571024, PMID:42263917].
Background
Rudbeckia hirta L. is a flowering plant in the Asteraceae family native to North America [PMID:30727400]. It is widely used as an ornamental plant in urban green spaces and gardens [PMID:37375871, PMID:30727400].
Traditional uses
The plant has been traditionally utilized in Native American medicine for the management of inflammatory conditions and digestive ailments [PMID:42263917].
Active compounds
Phytochemical analysis of the flowers has revealed over 250 compounds, including sesquiterpene lactones, polyphenolic acids, flavonoids, amino acids, and fatty acids [PMID:37571024]. Specific identified metabolites include 10 phenolic metabolites (three phenolic acids, two phenolic acid esters, four flavonol glycosides, and a trimethylated flavonol) [PMID:24678714], as well as the pseudoguaianolide rudbeckolide [PMID:23962140].
Mechanism of action
The plant extract demonstrates 5-lipoxygenase (5-LOX) inhibitory activity [PMID:24678714, PMID:23962140] and inhibits the NF-κB and C-X-C motif chemokine signaling pathways, which are associated with inflammation and cytokine storms [PMID:42263917]. It also exhibits antioxidant properties via iron chelation and 15-LOX inhibition [PMID:37571024].
Clinical evidence
Evidence DColitis (Rat Model)
Methanolic extract of aerial parts (RHME) showed protective potentials against colitis induced by acetic acid, inhibiting NF-κB and chemokine-mediated immune cell recruitment [PMID:42263917]
Evidence DBacterial/Fungal Infections (In Vitro)
Extracts exhibited inhibitory activity against Gram-positive bacteria and promising antifungal activity [PMID:37571024]
Evidence DCancer (In Vitro)
The extract demonstrated inhibition of cell growth, specifically on the MCF-7 cell line [PMID:37571024]
Evidence summary
The current evidence is primarily based on in vitro studies and animal models (rat colitis), indicating potential anti-inflammatory and antioxidant activities, but lacks human clinical trials.
PubMed sources
- 1.PMID: 37571024 (2023) — Preliminary Phytochemical and Biological Evaluation of Rudbeckia hirta Flowers. · Plants (Basel, Switzerland)
- 2.PMID: 24678714 (2014) — Evidence-based medicinal value of Rudbeckia hirta L. flowers. · Natural product research
- 3.PMID: 37375871 (2023) — Histological and Physiological Effects of Treatment of Rudbeckia hirta with Gamma Radiation. · Plants (Basel, Switzerland)
- 4.PMID: 30727400 (2012) — First Report of Leaf Spot of Rudbeckia hirta var. pulcherrima Caused by Septoria rudbeckiae in Korea. · Plant disease
- 5.PMID: 42263917 (2026) — Metabolomics profiling and anti-colitic activity of Rudbeckia hirta aerial parts: Inhibition of NF-κB, cytokine storm, and chemokine-mediated immune cell recruitment.